An Open Label Phase I Dose Escalation Study Of E7080
Phase of Trial: Phase I
Latest Information Update: 04 Apr 2018
At a glance
- Drugs Lenvatinib (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions
- Sponsors Eisai Inc
- 19 Apr 2019 Planned End Date changed to 1 Dec 2016.
- 31 May 2017 Results (n= 452) assessing optimal lenvatinib dose based on population PK and exposure-response analysis using using pooled data from NCT00946153, NCT00121719, NCT00121680, NCT00280397, NCT01268293 and other 8 phase 1 studies in healthy adults, published in the Journal of Clinical Pharmacology
- 27 Jul 2015 Status changed from active, no longer recruiting to completed according to results published in the Clinical cancer research: an official journal of the American Association for Cancer Research.